Itraconazole: Difference between revisions
From IDWiki
No edit summary |
(→) |
||
| Line 7: | Line 7: | ||
* Target in treatment is a trough >0.5 mg/L |
* Target in treatment is a trough >0.5 mg/L |
||
| − | == Adverse |
+ | == Adverse Drug Reactions == |
| − | * [[ |
+ | * [[Adverse drug reaction::Headache]] |
| − | * [[ |
+ | * [[Adverse drug reaction::Relative adrenal insufficiency]] |
| − | * [[ |
+ | * [[Adverse drug reaction::Hepatotoxicity]] |
| − | * [[ |
+ | * [[Adverse drug reaction::QTc prolongation]] |
[[Category:Antifungals]] |
[[Category:Antifungals]] |
||
Revision as of 23:14, 17 February 2020
- Azole antifungal
- Indications include Alternaria, Blastomyces dermatitidis, Chromoblastomycosis, Coccidioides immitis, Cryptococcus, Entomophthoromycotina, Exophiala, Exserohilum, Fonsecaea, Histoplasma capsulatum, Mycetoma, Paracoccidioides brasiliensis, Sappinia diploidea, Sporothrix schenckii
Therapeutic Drug Monitoring
- Should be measured 5 to 7 days after starting or changing the dose, or when interacting medications are changed
- Target in prophylaxis is a trough ot 0.5 mg/L
- Target in treatment is a trough >0.5 mg/L
